KWKarolina Winsko-SzczęSnowicz

Karolina Winsko-SzczęSnowicz

*This is an algorithmically generated author record based on publicly available information.

Karolina Winsko-SzczęSnowicz has a total of 60 co-authors. Here are the top co-authors by number of shared publications:

  • Mirosława Püsküllüoğlu

    Department of Clinical Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, Kraków, Poland

    3 shared publications
  • Aleksandra Konieczna

    Department of Breast Cancer and Reconstructive Surgery, Maria Sklodowska-Curie National Research Institute of Oncology-National Research Institute, Warsaw, Poland

    2 shared publications
  • Aleksandra Łacko

    Department of Oncology, Breast Unit Clinical Oncology Day Care Department, Wroclaw Medical University, Lower Silesian Comprehensive Cancer Center, Wrocław, Poland

    2 shared publications
  • Anika PęKala

    Department of Proliferative Diseases, Nicolaus Copernicus Multidisciplinary Centre for Oncology and Traumatology, Łódź, Poland

    2 shared publications
  • Bogumiła Czartoryska-Arłukowicz

    Department of Clinical Oncology, M. Sklodowska-Curie Bialystok Oncology Center, Białystok, Poland

    2 shared publications
  • Iveta KolářOvá

    Department of Oncology and Radiotherapy, Faculty of Medicine in Hradec Kralove and University Hospital in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic

    2 shared publications

Latest Publications

  • Combined positive score status in metastatic triple-negative breast cancer patients treated with sacituzumab govitecan: associated clinical characteristics and testing patterns in a Central European cohort

    by Karolina Winsko-SzczęSnowicz, Małgorzata Pieniążek, Anna Polakiewicz-Gilowska, Marcin Kubeczko, Miloš Holánek, Miroslava Malejčíková, Renáta Soumarová, Hana Študentová, Aleksandra Konieczna, Agnieszka Młodzińska, et al.

    Background Programmed death ligand 1 (PD-L1) expression, assessed by the combined positive score (CPS), is an established predictive biomarker for first-line chemo-immunotherapy in metastatic triple-negative breast cancer (mTNBC). In routine practice, CPS testing is heterogeneous and its relationship with outcomes in later-line, sacituzumab govitecan (SG)-treated patients with mTNBC is not well described. We aimed to assess clinicopathological correlates of CPS and its association with survival in this cohort. Methods We conducted a retrospective, multicenter study within the Central European Breast Cancer Collaboration (CEBCC)-102 project. CPS was locally assessed by validated immunohistochemistry. Survival outcomes: overall survival (OS), post-metastatic survival (PMS), and metastasis-free interval, were assessed with the Kaplan–Meier method. Results Of 303 women from the Czech Republic, Poland, and Slovakia with mTNBC treated with SG in ≥ 2 line, 107 (35.3%) with available CPS results were included in this analysis. CPS was positive (≥ 10) in 51/107 patients (47.7%) without significant demographic or disease-specific differences. During a median follow-up of 40 months, CPS-positive status may suggest worse outcomes in this cohort in multivariate analysis despite partial first-line chemo-immunotherapy exposure: OS 41.6 versus 67.7 months (HR 2.2, 95% CI: 1.1–4.5, p = 0.027) and PMS 20.2 versus 27.1 months (HR = 2.3, 95% CI: 1.2–4.2, p = 0.009). Conclusions In this selected cohort, CPS status did not correlate with clinicopathological characteristics, but CPS-positive status was associated with inferior survival outcomes. Given the selection and survivor bias inherent to later-line treatment cohorts and the incomplete availability of CPS, these findings should be considered hypothesis-generating. Graphical abstract


  • Open Access

    Timing of final oncologist visit and systemic treatment use near the end of life in pretreated patients with metastatic triple-negative breast cancer: a multinational cohort study

    by Justyna Żubrowska, Małgorzata Pieniążek, Anna Polakiewicz-Gilowska, Lenka Rušinová, Renáta Soumarová, Hana Študentová, Aleksandra Konieczna, Agnieszka Młodzińska, Karolina Winsko-Szczęsnowicz, Maja Lisik-Habib, et al.

  • Germline BRCA1/2 Mutations and Outcomes of First-Line Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer: A CEBCC-101 Biomarker Subanalysis

    by Karolina Winsko-SzczęSnowicz, Aleksandra Konieczna, Katarzyna Świderska, Miloš Holánek, Roman Dubiański, Lenka Rušinová, Małgorzata Pieniążek, Anika PęKala, Dana Dvořáková, Renata Soumarová, et al.

    Background: Germline BRCA1/2 mutations may influence sensitivity to systemic therapy in triple-negative breast cancer (TNBC), but their association with outcomes of first-line pembrolizumab plus chemotherapy remains uncertain. This study aimed to assess the association between germline BRCA1/2 mutation status and treatment outcomes in patients with programmed death-ligand 1 (PD-L1) combined positive score (CPS) ≥10 advanced TNBC receiving first-line pembrolizumab plus chemotherapy. Methods: This planned biomarker subanalysis of the retrospective, 20-centre CEBCC-101 cohort included 139 patients with documented germline BRCA1/2 status (gBRCA1/2m, n = 23; gBRCA1/2wt, n = 116). Objective response rate (ORR), progression-free survival (PFS) and overall survival (OS) were evaluated using univariable and multivariable analyses. Results: Patients with gBRCA1/2m were younger than those with gBRCA1/2wt (median 51.5 vs. 56.3 years; p = 0.038), with no other significant differences in assessed baseline characteristics. ORR was 78.3% versus 52.2%, respectively (p = 0.038; adjusted OR 6.172, 95% CI 1.581–24.091; p = 0.009). Median PFS was 11.1 versus 8.3 months (log-rank p = 0.181; adjusted HR 0.602, 95% CI 0.331–1.096; p = 0.097) and median OS was 26.1 versus 20.4 months (log-rank p = 0.244; adjusted HR 0.427, 95% CI 0.183–0.996; p = 0.049). No statistically significant differences in the analysed grade ≥ 2 adverse-event categories were detected. Conclusions: In this planned CEBCC-101 subanalysis, documented germline BRCA1/2 status was associated with a higher ORR during first-line pembrolizumab plus chemotherapy. Without a chemotherapy-only comparator, this association cannot be attributed specifically to pembrolizumab and may partly reflect greater sensitivity to DNA-damaging chemotherapy. No statistically significant safety differences were detected. Survival findings remain exploratory.